Early treatment with disease-modifying anti-rheumatic drugs (DMARDs)-alone or in combination-can prevent joint damage and minimize disability. Until recently, the DMARDs used predominantly in patients with rheumatoid arthritis had been methotrexate, sulfasalazine, and hydoxychloroquine. Older DMARDs such as gold, D-penicillamine, and azathioprine have fallen out of favor because of their long-term toxicities or modest benefit. Six newer DMARDs-leflunomide, etanercept, infliximab, adalimumab, rituximab, and anakinra-have greatly expanded the current treatment options.
|Original language||English (US)|
|Number of pages||12|
|State||Published - Aug 1 2005|
- Disease-modifying anti-rheumatic drugs
- Rheumatoid arthritis
ASJC Scopus subject areas